ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

Expert Review of Neurotherapeutics is an esteemed journal published by Taylor & Francis Ltd, focusing on the rapidly evolving field of neurotherapeutics. With an ISSN of 1473-7175 and an E-ISSN of 1744-8360, this publication aims to bridge the gap between clinical and preclinical research, providing a platform for innovative therapeutic strategies in neurology and neuroscience. The journal boasts impressive impact factor rankings, categorized as Q2 in both clinical neurology and miscellaneous neuroscience, and Q1 in medical pharmacology for 2023. Its reputable placement in Scopus rankings, including Rank #82/400 in clinical neurology, underscores its significance within the medical research community. Spanning from 2001 to 2024, the journal publishes critical reviews and original research articles aimed at enhancing understanding and treatment in neurological disorders. Although it currently does not offer open access, articles published in the journal are crucial for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in neurotherapeutics. With its strong emphasis on rigorous peer-reviewed content, Expert Review of Neurotherapeutics continues to be a vital resource for those dedicated to improving patient outcomes in the realm of neurology.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

Therapeutic Advances in Chronic Disease is a distinguished open-access journal published by SAGE Publications Ltd, with a focus on innovative research and clinical practices addressing chronic diseases—a field increasingly relevant in today's healthcare landscape. Since its inception in 2010, the journal has committed itself to disseminating high-quality research that informs both theory and practice. With an impressive impact factor and ranked Q1 in Medicine (miscellaneous) in 2023, this journal boasts recognition as one of the top-tier publications in the medical community, placing it in the 79th percentile among its peers. Accessible since 2019, it aims to bridge the gap between cutting-edge research and its application in improving patient outcomes, inviting contributions from researchers, clinicians, and health professionals. The journal's comprehensive scope encompasses various aspects of chronic disease management, making it an invaluable resource for those seeking to advance their understanding of this critical field.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.

SPINAL CORD, published by SpringerNature, is an esteemed peer-reviewed journal focusing on critical advancements in the fields of neurology, rehabilitation, and related disciplines. With an ISSN of 1362-4393 and E-ISSN 1476-5624, this journal has made significant contributions to the understanding and treatment of spinal cord disorders since its inception in 1996. Aiming to provide a platform for innovative research, it has achieved impressive rankings in various categories, such as Q1 in Rehabilitation, reflecting its influence and relevance in the academic community. SPINAL CORD is recognized within the top tier of journals, with notable Scopus rankings placing it in the 80th percentile for Rehabilitation. The journal is committed to open access, ensuring unrestricted availability of its research to foster knowledge dissemination. Operating from its UK base in London, this journal is essential for researchers, healthcare professionals, and students who seek to deepen their understanding of spinal injuries, advancements in clinical practices, and rehabilitation methodologies.

RESTORATIVE NEUROLOGY AND NEUROSCIENCE, published by IOS PRESS, is a premier journal dedicated to advancing the fields of neurology and neuroscience. Since its inception in 1989, this journal has played a crucial role in disseminating cutting-edge research findings and innovative therapeutic approaches that aim to restore neurological function and improve patient outcomes. With a focus on developmental neuroscience and clinical neurology, the journal holds a 2023 Scopus ranking of #129 out of 400 in clinical neurology, and #15 out of 37 in developmental neuroscience, reflecting its significant influence in these domains. Although it operates on a non-open access model, RESTORATIVE NEUROLOGY AND NEUROSCIENCE offers valuable insights for researchers, healthcare professionals, and students seeking to deepen their understanding of neural restoration mechanisms and therapeutic strategies. Located in Amsterdam, Netherlands, the journal continues to foster scholarly dialogue and innovation, contributing to the global advancement of neuroscience and neurology.

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.